Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - octreotide acetate - solution for injection - 100microgram/1ml

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - octreotide acetate - solution for injection - 200microgram/1ml

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - octreotide acetate - solution for injection - 500microgram/1ml

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - octreotide acetate 11.2mg equivalent to octreotide 10 mg;   - powder for injection with diluent - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer 188 water for injection - treatment of patients with acromegaly; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-enteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas/zollinger-ellison syndrome - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - octreotide acetate 22.4mg equivalent to octreotide 20 mg;   - powder for injection with diluent - 20 mg - active: octreotide acetate 22.4mg equivalent to octreotide 20 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer 188 water for injection - treatment of patients with acromegaly; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-enteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas/zollinger-ellison syndrome - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - octreotide acetate 33.6mg equivalent to octreotide 30 mg;   - powder for injection with diluent - 30 mg - active: octreotide acetate 33.6mg equivalent to octreotide 30 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer 188 water for injection - treatment of patients with acromegaly; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-enteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas/zollinger-ellison syndrome - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - octreotide -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sun pharmaceuticals industries australia pty ltd - octreotide -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - octreotide -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - octreotide -